ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS

(19)

(11)

EP 3 363 797 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 2 (W2 B1)

(48)	Corrigendum issued on:
	10.03.2021 Bulletin 2021/10

(45)	Mention of the grant of the patent:
	02.12.2020 Bulletin 2020/49

(21)	Application number: 17208659.7

(22)	Date of filing: 12.07.2010

(51)

International Patent Classification (IPC):

C07D 401/12^(2006.01)
C07D 407/14^(2006.01)
C07D 471/04^(2006.01)
A61K 31/437^(2006.01)
A61K 31/444^(2006.01)
A61K 31/506^(2006.01)
A61P 25/28^(2006.01)
A61P 37/00^(2006.01)
A61K 31/5377^(2006.01)
A61K 31/4709^(2006.01)

C07D 401/14^(2006.01)
C07D 413/14^(2006.01)
C07D 491/048^(2006.01)
A61K 31/4439^(2006.01)
A61K 31/497^(2006.01)
A61P 9/00^(2006.01)
A61P 29/00^(2006.01)
A61K 31/585^(2006.01)
A61K 31/496^(2006.01)
A61K 45/06^(2006.01)

(54)	ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS ORALE DARREICHUNGSFORM VON APOPTOSESIGNALREGULIERENDE KINASEHEMMERN FORME DE DOSAGE ORALE D'INHIBITEURS DE KINASE RÉGULANT LE SIGNAL D'APOPTOSE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)

Priority:

13.07.2009 US 225076 P
13.07.2009 US 225079 P
22.12.2009 US 289263 P

(43)	Date of publication of application:
	22.08.2018 Bulletin 2018/34

(60)	Divisional application:
	20210819.7

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	15151030.2 / 2933252
	10733116.7 / 2454250

(73)	Proprietor: Gilead Sciences, Inc.
	Foster City, CA 94404 (US)

(72)	Inventors:
	CORKEY, Britton Foster City, CA 94404 (US) GRAUPE, Michael Pacifica CA 94044 (US) KOCH, Keith Erie CO 80516 (US) MELVIN, Lawrence S. Longmont CO 80504 (US) NOTTE, Gregory San Mateo CA 9441 (US)

(74)	Representative: Wallace, Sheila Jane
	Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW London EC4A 1BW (GB)

(56)

References cited: :

EP-A1- 2 058 309

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).